These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 12469936)

  • 1. Antidepressant drugs and cytokines in mood disorders.
    Nishida A; Hisaoka K; Zensho H; Uchitomi Y; Morinobu S; Yamawaki S
    Int Immunopharmacol; 2002 Nov; 2(12):1619-26. PubMed ID: 12469936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New approaches to antidepressant drug design: cytokine-regulated pathways.
    Nishida A; Miyaoka T; Inagaki T; Horiguchi J
    Curr Pharm Des; 2009; 15(14):1683-7. PubMed ID: 19442181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-HT1B receptors: a novel target for lithium. Possible involvement in mood disorders.
    Massot O; Rousselle JC; Fillion MP; Januel D; Plantefol M; Fillion G
    Neuropsychopharmacology; 1999 Oct; 21(4):530-41. PubMed ID: 10481837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. III. Effect of antidepressants and lithium carbonate.
    Meltzer HY; Lowy M; Robertson A; Goodnick P; Perline R
    Arch Gen Psychiatry; 1984 Apr; 41(4):391-7. PubMed ID: 6422900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants.
    Chen G; Hasanat KA; Bebchuk JM; Moore GJ; Glitz D; Manji HK
    Psychosom Med; 1999; 61(5):599-617. PubMed ID: 10511011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions.
    Lerer B; Macciardi F
    Int J Neuropsychopharmacol; 2002 Sep; 5(3):255-75. PubMed ID: 12366879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galanin receptor antagonists : a potential novel pharmacological treatment for mood disorders.
    Ogren SO; Kuteeva E; Hökfelt T; Kehr J
    CNS Drugs; 2006; 20(8):633-54. PubMed ID: 16863269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature.
    Costemale-Lacoste JF; Guilloux JP; Gaillard R
    Encephale; 2016 Apr; 42(2):156-64. PubMed ID: 26995153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidepressant treatments in children and adolescents. I. Affective disorders.
    Ambrosini PJ; Bianchi MD; Rabinovich H; Elia J
    J Am Acad Child Adolesc Psychiatry; 1993 Jan; 32(1):1-6. PubMed ID: 8428861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments.
    Krystal JH; Sanacora G; Blumberg H; Anand A; Charney DS; Marek G; Epperson CN; Goddard A; Mason GF
    Mol Psychiatry; 2002; 7 Suppl 1():S71-80. PubMed ID: 11986998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circadian rhythm mechanisms in affective illness and in antidepressant drug action.
    Wehr TA; Wirz-Justice A
    Pharmacopsychiatria; 1982 Jan; 15(1):31-9. PubMed ID: 7038719
    [No Abstract]   [Full Text] [Related]  

  • 12. Inflammation-Related Changes in Mood Disorders and the Immunomodulatory Role of Lithium.
    Sakrajda K; Szczepankiewicz A
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33546417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effects of antidepressant and mood stabilizing drugs.
    Young LT
    J Psychiatry Neurosci; 2002 Jan; 27(1):8-9. PubMed ID: 11836978
    [No Abstract]   [Full Text] [Related]  

  • 14. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
    Gould TD; Manji HK
    Neuropsychopharmacology; 2005 Jul; 30(7):1223-37. PubMed ID: 15827567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitric oxide signalling and antidepressant action revisited.
    Joca SRL; Sartim AG; Roncalho AL; Diniz CFA; Wegener G
    Cell Tissue Res; 2019 Jul; 377(1):45-58. PubMed ID: 30649612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia.
    Hudson CJ; Young LT; Li PP; Warsh JJ
    Synapse; 1993 Mar; 13(3):278-93. PubMed ID: 8497811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphological brain changes in depression: can antidepressants reverse them?
    Miguel-Hidalgo JJ; Rajkowska G
    CNS Drugs; 2002; 16(6):361-72. PubMed ID: 12027783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New therapeutic strategy for mood disorders.
    Crupi R; Marino A; Cuzzocrea S
    Curr Med Chem; 2011; 18(28):4284-98. PubMed ID: 21861822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics.
    Manji HK; Duman RS
    Psychopharmacol Bull; 2001; 35(2):5-49. PubMed ID: 12397885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Astroglial Connexin43 as a Potential Target for a Mood Stabiliser.
    Okada M; Oka T; Nakamoto M; Fukuyama K; Shiroyama T
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.